ZA943465B - Transforming growth factor alpha H1 - Google Patents

Transforming growth factor alpha H1

Info

Publication number: ZA943465B
Authority: ZA; South Africa
Prior art keywords: alpha; polypeptide; growth factor; transforming growth; factor alpha
Prior art date: 1994-03-08

Application number

ZA943465A

Other languages

English (en)

Inventor

Paul S Meissner

Rebeca Fuldner

Mark D Adams

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-08

Filing date

1994-05-19

Publication date

1995-11-20

1994-05-19 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

1995-11-20 Publication of ZA943465B publication Critical patent/ZA943465B/xx

Links

NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 title 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 title 1
101800004564 Transforming growth factor alpha Proteins 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
239000005557 antagonist Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
101500027527 Homo sapiens Transforming growth factor alpha Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000008024 pharmaceutical diluent Substances 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Crystallography & Structural Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA943465A 1994-03-08 1994-05-19 Transforming growth factor alpha H1 ZA943465B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/208,008 US5633147A (en)	1994-03-08	1994-03-08	Transforming growth factor αH1

Publications (1)

Publication Number	Publication Date
ZA943465B true ZA943465B (en)	1995-11-20

Family

ID=22772852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA943465A ZA943465B (en)	1994-03-08	1994-05-19	Transforming growth factor alpha H1

Country Status (14)

Country	Link
US (1)	US5633147A (de)
EP (2)	EP1063293A3 (de)
JP (1)	JPH09509846A (de)
KR (1)	KR970701776A (de)
CN (1)	CN1087344C (de)
AT (1)	ATE205254T1 (de)
AU (1)	AU681406B2 (de)
CA (1)	CA2184583A1 (de)
DE (1)	DE69428214T2 (de)
DK (1)	DK0759067T3 (de)
ES (1)	ES2161246T3 (de)
PT (1)	PT759067E (de)
WO (1)	WO1995024466A1 (de)
ZA (1)	ZA943465B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020188110A1 (en) *	1994-03-08	2002-12-12	Human Genome Sciences, Inc.	Transforming growth factor alpha HI
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US6074839A (en)	1994-03-08	2000-06-13	Human Genome Sciences, Inc.	Transforming growth factor αHI
US6608182B1 (en) *	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US6040157A (en) *	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6734285B2 (en)	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
US7153827B1 (en)	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
EP0751992B1 (de) *	1994-03-08	2005-11-09	Human Genome Sciences, Inc.	Vaskularer endothelialer wachstumsfaktor 2
US6030613A (en)	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
US6410506B1 (en) *	1995-05-19	2002-06-25	Human Genome Sciences, Inc.	Transforming growth factor α HII
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7294482B2 (en) *	1998-11-19	2007-11-13	Millennium Pharmaceuticals, Inc.	EGF-like nucleic acids
AU2153500A (en) *	1998-11-19	2000-06-05	Millennium Pharmaceuticals, Inc.	Egf-like nucleic acids and polypeptides and uses thereof
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
US20020099008A1 (en)	1999-04-26	2002-07-25	Daniel R. Twardzik	Method for stimulating hematopoiesis using tgf-alpha
DE60035192T2 (de)	1999-04-26	2008-02-14	Applied Protein Sciences, LLC, Mountain View	Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
CA2380635A1 (en) *	1999-08-19	2001-02-22	Applied Protein Sciences, Llc	Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en)	1999-08-19	2002-12-19	Stem Cell Pharmaceuticals, Inc.	TGF-alpha polypeptides, functional fragments and methods of use therefor
AU2001268427B2 (en)	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US7273751B2 (en) *	2000-08-04	2007-09-25	Human Genome Science, Inc.	Vascular endothelial growth factor-2
AU2001288301A1 (en)	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
GB0020953D0 (en) *	2000-08-24	2000-10-11	Smithkline Beecham Biolog	Vaccine
DE60236646D1 (de)	2001-04-13	2010-07-22	Human Genome Sciences Inc	Anti-VEGF-2 Antikörper
US7402312B2 (en) *	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002252631A1 (en) *	2001-04-13	2002-10-28	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20050232921A1 (en) *	2001-04-13	2005-10-20	Rosen Craig A	Vascular endothelial growth factor 2
WO2002083850A2 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
WO2004089357A2 (en) *	2003-04-02	2004-10-21	Regents Of The University Of Minnesota	Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
AU2008312457B2 (en) *	2007-10-19	2014-04-17	Genentech, Inc.	Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI890312L (fi) *	1988-01-25	1989-07-26	Oncogen	Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
US5115096A (en) *	1988-04-15	1992-05-19	Oncogen	Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) *	1990-05-29	1993-10-26	The Government Of The United States	Human cripto protein

1994
- 1994-03-08 US US08/208,008 patent/US5633147A/en not_active Expired - Lifetime
- 1994-05-12 AU AU68350/94A patent/AU681406B2/en not_active Ceased
- 1994-05-12 EP EP00120470A patent/EP1063293A3/de not_active Withdrawn
- 1994-05-12 CA CA002184583A patent/CA2184583A1/en not_active Abandoned
- 1994-05-12 DK DK94916791T patent/DK0759067T3/da active
- 1994-05-12 WO PCT/US1994/005476 patent/WO1995024466A1/en not_active Ceased
- 1994-05-12 AT AT94916791T patent/ATE205254T1/de not_active IP Right Cessation
- 1994-05-12 EP EP94916791A patent/EP0759067B1/de not_active Expired - Lifetime
- 1994-05-12 CN CN94195051A patent/CN1087344C/zh not_active Expired - Fee Related
- 1994-05-12 ES ES94916791T patent/ES2161246T3/es not_active Expired - Lifetime
- 1994-05-12 PT PT94916791T patent/PT759067E/pt unknown
- 1994-05-12 DE DE69428214T patent/DE69428214T2/de not_active Expired - Fee Related
- 1994-05-12 JP JP7523424A patent/JPH09509846A/ja not_active Ceased
- 1994-05-12 KR KR1019960704894A patent/KR970701776A/ko not_active Ceased
- 1994-05-19 ZA ZA943465A patent/ZA943465B/xx unknown

Also Published As

Publication number	Publication date
ATE205254T1 (de)	2001-09-15
ES2161246T3 (es)	2001-12-01
KR970701776A (ko)	1997-04-12
AU6835094A (en)	1995-09-25
EP1063293A3 (de)	2001-07-11
PT759067E (pt)	2002-02-28
WO1995024466A1 (en)	1995-09-14
CA2184583A1 (en)	1995-09-14
EP0759067B1 (de)	2001-09-05
EP1063293A2 (de)	2000-12-27
JPH09509846A (ja)	1997-10-07
US5633147A (en)	1997-05-27
DE69428214T2 (de)	2002-06-27
DK0759067T3 (da)	2001-10-22
DE69428214D1 (de)	2001-10-11
AU681406B2 (en)	1997-08-28
EP0759067A1 (de)	1997-02-26
CN1087344C (zh)	2002-07-10
CN1143386A (zh)	1997-02-19
EP0759067A4 (de)	1997-10-22

Publication	Publication Date	Title
DE69428214D1 (de)	2001-10-11	Transformierender wachstumsfaktor alpha h1
ZA943464B (en)	1995-11-20	Vascular endothelial growth factor 2
EP0787802A3 (de)	1997-08-27
HUP0103758A2 (hu)	2002-01-28	Neurotróf faktorok
NZ271756A (en)	1998-02-26	Human macrophage inflammatory proteins and coding sequences, their production and use
GB9224584D0 (en)	1993-01-13	Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
EP0853121A3 (de)	1998-08-05	Menschliche DNase
ZA951008B (en)	1996-10-18	N-terminally chemically modificed protein compositions and method
AU2608292A (en)	1992-12-17	Human immunoglobulins produced by recombinant dna techniques
ZA896715B (en)	1990-09-26	Fusion protein of paramyxovirus,method of production using recombinant baculovirus expression vector,vaccine comprising such protein and use thereof
DE69333885D1 (en)	2006-02-23	C-c ckr-1, ein c-c chemokin rezeptor
AU1724795A (en)	1996-07-03	Human tissue inhibitor of metalloproteinase-4
CA2050058A1 (en)	1992-02-28	Recombinant mite allergen
CA2295199A1 (en)	1999-01-28	Method for treating vascular proliferative diseases with p27 and fusions thereof
CA2096010A1 (en)	1992-05-17	Recombinant feline coronavirus s proteins
EP0361284A3 (de)	1990-09-05	T-Zellen-Wachstumsfaktor
NZ335633A (en)	2000-10-27	Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
HUT50195A (en)	1989-12-28	New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
GB2171703B (en)	1989-11-15	Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
NO890174L (no)	1989-07-17	Rekombinante interleukin-1alfa-polypeptider.
CA2089111A1 (en)	1993-08-11	Smooth muscle mitogen and isolated dna coding therefor
CA2050477A1 (en)	1991-07-09	T cell growth factor
AU2459188A (en)	1989-05-04	Anticoagulative protein pp4-x, and its preparation and use
WO2001075008A3 (fr)	2002-02-07	Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide
WO2001068693A8 (fr)	2001-11-01	Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide